Mallinckrodt Statement on U.S. Department of Justice Generics Industry Investigation
Mallinckrodt has seen reports that the U.S. Department of Justice's Antitrust Division has been investigating generic drug manufacturers in connection with alleged price collusion involving approximately two dozen drugs. The company does not have direct knowledge of these investigations nor the alleged conduct. Consistent with U.S. Securities and Exchange Commission (SEC) rules, Mallinckrodt makes public disclosure regarding material events related to government investigations in our periodic reports filed with the SEC.
November 7, 2016